Agenus Will Present Metastatic Cancer Data in Phoenix
Researchers will share findings on investigational immunotherapy treatments at a conference this November.
Updated on Oct. 2, 2026 in Cancer
At the upcoming Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting in Phoenix, Agenus will present new research on combination cancer immunotherapies. Clinical and translational data from trials involving over 1,000 patients will be featured during the event, which runs from November 4-8, 2026.
Why it matters
The upcoming presentations offer a look at potential advances in treating metastatic colorectal cancer using combinations of investigational drugs. Understanding these long-term survival trends may help shape future therapeutic options for patients managing advanced malignancies.
Agenus reports clinical and translational data derived from a cumulative cohort of 1,300 patients evaluated in clinical trials. These findings focus on the immunotherapy agents botensilimab and balstilimab, though the study outcomes are considered preliminary until peer-reviewed publication.
The players
Agenus
A biotechnology company founded in 1994 that specializes in the development of immunotherapies for cancer treatment.
Anthony El-Khoueiry
A medical researcher scheduled to present clinical data regarding long-term survival in metastatic colorectal cancer patients.
Shanmugarajan Krishnan
A researcher specializing in translational science who will present data on combined immunotherapy and cell therapy protocols.
The details
The research highlights combinations of botensilimab and balstilimab, which are designed to modulate the immune system's response to tumors. Additionally, investigators are studying the integration of agenT-797, a cell therapy agent, to explore its potential to enhance therapeutic efficacy. These findings, scheduled for display in the North Building exhibition halls, examine how such multi-agent protocols may improve survival rates in advanced colorectal cancer.
Timeline
The SITC 2026 Annual Meeting will occur from November 4-8, 2026.
Presentations of research posters are scheduled for November 7, 2026.
Health Landscape
The SITC Annual Meeting serves as a major forum for sharing emerging immunotherapy research in the oncology field. This presentation continues the industry-wide shift toward exploring combination regimens to overcome resistance in metastatic cancers.
These findings are currently limited to clinical trial settings and do not represent a change in clinical practice or established treatment protocols. If you are managing metastatic cancer, discuss emerging research and potential trial eligibility with your primary oncologist.
The takeaway
Ongoing immunotherapy research, such as the studies being presented by Agenus, continues to investigate new ways to extend survival in metastatic colorectal cancer. Patients should track updates from these conferences by discussing new clinical trial evidence with their specialist.
What happens next
Agenus researchers Anthony El-Khoueiry and Shanmugarajan Krishnan are scheduled to present their respective posters at the SITC 2026 Annual Meeting in the North Building of the Phoenix convention area on November 7, 2026.
Further reading
For more information on the current landscape of oncology research and treatment, visit our Cancer section.
